article thumbnail

Lessons from Monte Carlo Models: Why Drug Development is Hard

DrugBaron

“There is more than one way to skin a cat” is a rather gruesome British idiom, but its sentiment surely applies to running a successful pharmaceutical portfolio. So what does the game look like to a late-stage investor or a pharma company head of R&D thinking about portfolio prioritisation?

article thumbnail

Which pharma companies have the most supplementary protection certificates?

Drug Patent Watch

This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the… The post Which pharma companies have the most supplementary protection certificates?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Which pharma companies have the most supplementary protection certificates?

Drug Patent Watch

This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the…. The post Which pharma companies have the most supplementary protection certificates?

article thumbnail

Which pharma companies have the most supplementary protection certificates?

Drug Patent Watch

This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the…. The post Which pharma companies have the most supplementary protection certificates?

article thumbnail

Which pharma companies have the most supplementary protection certificates?

Drug Patent Watch

This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the…. The post Which pharma companies have the most supplementary protection certificates?

article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector.

article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. To address these challenges, many companies outsource their clinical trials to contract research organizations (CROs) with established protocols, global reach, and therapeutic area expertise1.